Diamyd Medical is a clinical-stage diabetes company active in the field of pharmaceutical development.
They develop two novel disease-modifying drugs: the antigen-specific immunotherapy Diamyd® and the oral regenerative and immunomodulatory therapeutic Remygen®.
Diamyd® and Remygen® are evaluated in ongoing clinical studies. The therapies target the underlying causes of diabetes, dysfunction, and loss of the pancreas's insulin-producing cells.
Diamyd Medical’s shares are traded on Nasdaq First North Growth Market, ticker DMYD B.
To read more, please visit their website here.